A stock basher spreads rumors about a security to push the trading price down. Bashers may act on their own account or represent third parties, and may engage in a coordinated attack with a group of people to make their claims seem more legitimate. Individuals suggesting that a company might be headed for trouble might not attract attention, but multiple rumors appearing to originate from different sources are apt to be taken more seriously. Environments like Internet message boards can be particularly fertile ground for stock bashers.
This activity may be illegal under laws governing activities on the stock market, depending on regulations. They could be considered a form of securities fraud if bashers operate with the goal to drive prices down to damage a company or create an opportunity for investors.
Funny how they do show up when there is price movement.
some notable bashers; prd747, ave-morax, indeedmoremoney, among others
Pay the idiot no mind bio. As he stated; RXI was his first foray into biotech. Clearly he is angry because he cannot handle the timeframe of a developmental biotech. He lost money so he comes here to cry and bash, cry and bash. Pay him no mind, he's just angry at himself.............GL
sabaid, for someone who clearly dislikes RXI's prospects, you spend a lot time here touting your bearish comments. Now you equate RXI to a "soap opera". Clearly you hold Dr. Cauwenbergh and his staff in very low esteem with a comment like that. Doesn't matter to me of course, Just curious as to why you appear regularly to bash this company...........GL
prd, you are always so angry. Did they teach you that at stock bashing school? You really do sound veryangry and stupid. You posts add nothing of either value or interest here. BTW where has your girlfriend avi-moron been?
Because they have guidelines per the companies they invest in. Companies with tiny M/caps (TPIV @ $4m) and pps below $1 are far to speculative for their consideration......GL
ben, creams and gels treat pain, itch, and to some degree redness of scars. They do not diminish the growth of scars, which remains an unmet medical need.
Simply put, there are no drugs available that lessen the growth of scars and keloids. There are a few companies working on therapies currently. RXI has a very good prospect in three p2 trials which has shows solid efficacy i p1. Success in any of the three trials will both advance 109 to p3 as well as confirm sdrxRNA as a delivery method for ay number of RNAi drugs...................GL
hanna, the only answer I can give is that they simply are not complete IMO. Can't say if they are promising or not, only that they are not completed to the extent that they can report (my guess). Keep in mind, Dr. C. is both savvy and experienced. Keep in mind the p2 design encompasses three trials, any one of which which will advance rx-109 upon good results..............Just sit tight...........GL
is very interesting. They are here for a reason, and it's not to steal new investor's $. There aren't any new investors...............yet. GLTA
Gave the source see below. Just stumbled into, thought it might be a good abstract for those less familiar with RXI's development........GL
If I remember correctly Advanced and RXI have agreement per Adv given the right to market RXI's sdrxRNA for RXI for certain %. Will attempt to find this info, perhaps you will do same,,,,thnks
Completion of this project will createa foundation for developing the first line of sdRNAs based products for commercialization, which will be done as part of phase II proposal. Availability of these sdRNA reagents that are active in all cell types and in vivo will enable functional genomicsand target stratification/validation studies and have a major impact on the drug discovery process. PUBLIC HEALTH RELEVANCE: The utility of RNAi technology is severely limited by limited availability of efficient delivery of RNAi compounds to primary cells and in vivo. We have recently developed a new class of RNAi compounds, self- delivering rxRNA or sdRNA. sdRNA is a hydrophobically modified RNAi- antisense hybrid, which has been demonstrated to be highly efficacious in vitro in primary cells andin vivo upon local administration. Current proposal will focus on further optimizing this new class of compounds to enable rapid design and synthesis.
DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in efficient gene silencing. Unfortunately, while siRNA-based functional genomics is widely used in vitro, the ability to apply this technology to primary cells and in vivo target validation has been impeded limited availability of efficient and non-toxic delivery systems. We, in collaboration with RXi Pharmaceuticals, have developed a novel class of covalently modified RNAi compounds that do not require a delivery vehicle to enter cells and have improved pharmacology compared to traditional siRNAs. We term these compounds self- delivering RNA or sdRNA. sdRNA is a hydrophobically modified RNAi- antisense hybrid, which has beendemonstrated to be highly efficacious in vitro in primary cells and in vivo upon local administration. Robust uptake and/or silencing without toxicity has been demonstrated in several tissues including dermal, muscle, tumors, alveolar macrophages, spinal cord, retina etc. In dermal layer and retina, intradermal and intravitreal injections of sdRNA at 5g doses induce potent and long lasting silencing. RXi has utilized extensive screening to successfully identify functional sdRNA compounds against a number oftargets and are actively procuring some of these compounds toward clinical development. A major hurdle to commercialization of sdRNA as a superior functional genomics tool, enabling RNAi in primary cells and in vivo, is the relatively low hit rate as compared to conventional siRNAs. While the need to screen large number of sequences per gene is not a limiting factor for therapeutic applications, it severely limits the applicability of sdRNA technology to functional genomics, where cost effective compound selection against thousands of genes is required. The objective of this proposal is to optimize sdRNA structure, chemistry, targeting position, sequence preferences to develop an algorithm for sdRNA potency predic